The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer

The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer - The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017571

Enrollment

Registered

2015-05-14

Start date

2004-07-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Initiaion of bisphosphonate (risedronate or alendronate) when patients were diagnosed with osteoporosis having a T-score of -2.5 or lower.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Primary breast cancer in stage 0 to IIIC Treatment with anastrozole Postmenopausal E2 <30pg/ml Written informed concent

Exclusion criteria

Exclusion criteria: Patients already treated as osteoporosis

Design outcomes

Primary

Measure	Time frame
BMD change from baseline to 5 years at the lumbar spine and femoral neck	—

Secondary

Measure	Time frame
BMD change from baseline to 6, 12, 24, 36, 48 and 50 months at the lumbar spine and femoral neck Bone fracture rate during 5 years	—

Countries

Japan

Contacts

Public ContactAkira Hirano

Tokyo Women's Medical University Medical Center East Department of Breast Surgery

ahirasu@dnh.twmu.ac.jp03-3810-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026